Pfizer real-world study, BioNTech shows COVID-19 vaccine ‘significantly’ reduces cases, hospitalization and death

by

Pfizer Inc. PFE,
+ 1.39%
and BioNTech SE BNTX,
+ 1.60%,
together with the Israeli Ministry of Health, said a worldwide study showed “significantly lower” rates of COVID-19 cases in people who received the vaccine with the companies ’BNT162b2 vaccine. The data also showed that protection from COVID-19 is even stronger two weeks after taking the second dose. Vaccination efficacy was at least 97% against typical COVID-19 cases, hospital, acute and diagnostic hospitals and deaths, and 94% effective against asymptomatic SARS-CoV-2 infections. The data showed that those who were not vaccinated were 44 times more likely to develop symptomatic COVID-19 and 29 times more likely to die from COVID-19. Shares of Pfizer rose 0.4% and BioNTech collected 2.7% in pre-sale trading, while ES00 futures,
+ 0.68%
for the S&P 500 SPX,
+ 0.60%
received 0.7%.

.Source